Plant Name: Glycyrrhiza yunnanensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.587E-12 | 5.317E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.517E-11 | 4.636E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.075E-10 | 4.683E-07 | CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.212E-09 | 3.770E-06 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.907E-09 | 1.913E-05 | CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0044281; small molecule metabolic process | 2.178E-08 | 3.068E-05 | AKR1B1, ALDH1A1, CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP3A4, HPGD, HSD17B10, MAPK1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.254E-08 | 3.068E-05 | CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.626E-08 | 4.156E-05 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.642E-08 | 6.833E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.904E-08 | 6.833E-05 | CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.000E-07 | 3.629E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.322E-07 | 4.635E-04 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.803E-07 | 5.859E-04 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 8.861E-07 | 6.431E-04 | AKR1B1, ALDH1A1, CYP19A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.101E-06 | 7.262E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.022E-05 | 6.016E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 1.064E-05 | 6.098E-03 | AKR1B1, CYP19A1, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.532E-09 | 4.521E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.923E-08 | 5.398E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.265E-07 | 5.398E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.552E-07 | 1.165E-05 | CYP2C9; CYP1A2; ALDH1A1; AKR1B1; CYP2C19; CYP3A4; CYP19A1; HSD17B10 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.546E-07 | 8.148E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 8.236E-06 | 1.757E-04 | CYP1A2; CYP3A4; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.650E-05 | 3.017E-04 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.949E-05 | 9.519E-04 | CYP2C9; MAPK1; CYP2C19 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.155E-04 | 1.642E-03 | LMNA; MAPK1; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.104E-04 | 8.262E-03 | MAPK1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.400E-04 | 8.262E-03 | CYP2C9; CYP2C19 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 9.514E-04 | 8.262E-03 | MAPK1; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 7.104E-04 | 8.262E-03 | MAPK1; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.131E-03 | 8.262E-03 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.162E-03 | 8.262E-03 | MAPK1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.162E-03 | 8.262E-03 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.162E-03 | 8.262E-03 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 9.229E-04 | 8.262E-03 | MAPK1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.209E-03 | 1.196E-02 | MAPK1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.721E-03 | 1.049E-02 | MAPK1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.226E-03 | 8.262E-03 | MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.296E-03 | 1.196E-02 | MAPK1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.340E-03 | 1.196E-02 | MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.608E-03 | 1.029E-02 | MAPK1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.429E-03 | 1.196E-02 | MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.613E-03 | 1.239E-02 | MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.340E-03 | 1.196E-02 | MAPK1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.999E-03 | 1.322E-02 | MAPK1; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.099E-03 | 1.322E-02 | MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.099E-03 | 1.322E-02 | MAPK1; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 3.735E-03 | 1.470E-02 | MAPK1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.547E-03 | 1.712E-02 | MAPK1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.790E-03 | 1.470E-02 | MAPK1; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 6.465E-03 | 2.299E-02 | MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.973E-03 | 2.185E-02 | MAPK1; HSD17B10 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 6.681E-03 | 2.300E-02 | MAPK1; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 7.349E-03 | 2.412E-02 | MAPK1; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.773E-03 | 2.739E-02 | MAPK1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.286E-03 | 2.651E-02 | MAPK1; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 6.827E-03 | 2.300E-02 | HPGD; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.067E-02 | 3.251E-02 | MAPK1; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.332E-02 | 3.965E-02 | MAPK1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.495E-03 | 1.443E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; NFKB1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |